Côd QR

A multicentre, double-blind, placebo-controlled randomized trial of Mycobacterium w in critically ill patients with COVID-19 (ARMY-2)

Background: Mycobacterium w (Mw), an immunomodulator, resulted in better clinical status in severe coronavirus infectious disease 19 (COVID-19) but no survival benefit in a previous study. Herein, we investigate whether Mw could improve clinical outcomes and survival in COVID-19. Materials and Metho...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Inderpaul S Sehgal, Ritesh Agarwal, Atul Jindal, Md Sabah Siddiqui, Anant Mohan, Arnab Pal, Randeep Guleria, Ashish Bhalla, Kamal Kajal, Pankaj Malhotra, Goverdhan Dutt Puri, Sagar Khadanga, Rajnish Joshi, Sarman Singh, Saurabh Saigal, Nitin M Nagarkar, Vikas Suri, Sushma Bhatnagar, Pawan Tiwari, Mini P Singh, Laxmi Narayana Yaddanapudi, Saurabh Mittal, Anshika Chauhan, Gaurab Banerjee, Deependra K Rai, Bikram K Gupta
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer Medknow Publications 2024-01-01
Cyfres:Lung India
Pynciau:
coronavirus
covid
mycobacterium indicus pranii
mw
mycobacterium w
Mynediad Ar-lein:http://www.lungindia.com/article.asp?issn=0970-2113;year=2024;volume=41;issue=2;spage=84;epage=92;aulast=Sehgal
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg